Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.

Autor: Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Johnson DH; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Murthy R; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bentebibel SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Uemura MI; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hudgens CW; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Safa H; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., James M; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Andtbacka RHI; Surgical Oncology Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Johnson DB; Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Shaheen M; Department of Medicine and Cancer Center, University of Arizona, Tucson, Arizona., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rahimian S; Idera Pharmaceuticals, Inc., Exton, Pennsylvania., Chunduru SK; Idera Pharmaceuticals, Inc., Exton, Pennsylvania., Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tetzlaff MT; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Overwijk WW; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gabrail N; Department of Oncology, Gabrail Cancer Center, Canton, Ohio., Agrawal S; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts., Doolittle G; Department of Oncology, University of Kansas Medical Center, Kansas City, Kansas., Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York., Markowitz J; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. adiab@mdanderson.org cbernatchez@mdanderson.org., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. adiab@mdanderson.org cbernatchez@mdanderson.org.

Publikováno v: Cancer discovery [Cancer Discov] 2021 Aug; Vol. 11 (8), pp. 1996-2013. Date of Electronic Publication: 2021 Mar 11.

Development of CNS metastases and survival in patients with inflammatory breast cancer.

Autor: Uemura MI; Divison of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., French JT; Divison of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hess KR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Liu D; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Raghav K; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Arun BK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Valero V; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ueno NT; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas., Alvarez RH; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas., Woodward WA; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas., Debeb BG; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas., Moulder SL; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lim B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tripathy D; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ibrahim NK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Cancer [Cancer] 2018 Jun 01; Vol. 124 (11), pp. 2299-2305. Date of Electronic Publication: 2018 Mar 26.